Effect of adoptive T-cell immunotherapy on immunological parameters and prognosis in patients with advanced pancreatic cancer |
| |
| Authors: | Tatsuo Kumai Eishiro Mizukoshi Tomomi Hashiba Hidetoshi Nakagawa Masaaki Kitahara Tomoharu Miyashita Takafumi Mochizuki Shigenori Goto Takashi Kamigaki Rishu Takimoto Taro Yamashita Yoshio Sakai Tatsuya Yamashita Masao Honda Katsuro Tomita Shuichi Kaneko |
| |
| Affiliation: | 1. Department of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa, Japan;2. Kanazawa Advanced Medical Center, Kanazawa, Japan;3. Seta Clinic Group, Department of Next-Generation Cell and Immune Therapy, Juntendo University School of Medicine, Tokyo, Japan;1. Morphocell Technologies Inc, Montreal, QC, Canada;2. Steminent Biotherapeutics Inc, Vancouver, BC, Canada;3. International Society for Cell & Gene Therapy, Vancouver, BC, Canada;4. Truist Securities, New York, NY, USA;5. Aquilo Capital, LP, San Francisco, CA, USA;1. Department of Cornea and Refractive Surgery, Narayana Nethralaya Eye Institute, Bangalore, India;2. Stem Cell Research Laboratory, GROW Laboratory, Narayana Nethralaya Foundation, Bangalore, India;3. GROW Laboratory, Narayana Nethralaya Foundation, Bangalore, India;4. Department of Vitreo-Retinal Surgery, Narayana Nethralaya Eye Institute, Bangalore, India;1. Department of Hematology and Cell Therapy, Oran, Algeria;2. European Society for Blood and Marrow Transplantation Global Committee, Paris, France;3. Institut Paoli Calmettes, Cancer Research Center of Marseille, Aix Marseille University, Marseille, France;4. Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire, Nantes, France;5. University College London Cancer Institute, London, UK;6. Department of Hematology and Cell Therapy, Hospices Civils, Lyon, France;7. Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland;8. University of Freiburg, Freiburg, Germany;9. Policlinico Universitario Tor Vergata, Rome, Italy;10. Department of Hematology and Stem Cell Transplantation, Centre Hospitalier Universitaire, Bordeaux, France;11. Department of Hematology and Cell Therapy, Hôpital Saint-Antoine, Sorbonne University, Paris, France;1. Seattle Children''s Research Institute, Seattle, Washington, USA;2. University of California San Francisco, San Francisco, California, USA;3. Children''s Hospital Los Angeles, Los Angeles, California, USA;4. Center for Cancer and Immunology Research, Center for Cancer and Blood Disorders, Children''s National Hospital, Washington, DC, USA;5. The George Washington University, Washington, DC, USA;1. Anthony Nolan Cell Therapy Centre, Nottingham, UK;2. The Anthony Nolan Research Institute, Nottingham, UK |
| |
| Abstract: | Background aimsImmunotherapy is effective for many types of cancer, but its benefits in advanced pancreatic cancer, which has a poor prognosis, are not well established. In this study, the authors examined the effects of adoptive T-cell immunotherapy (ATI) on immune cell profiles and prognosis in patients with unresectable advanced pancreatic cancer.MethodsSeventy-seven patients with unresectable advanced pancreatic cancer were treated with six cycles of αβ T cells alone or in combination with chemotherapy or chemoradiation. Immune cell profiles in peripheral blood samples obtained before and after treatment were comprehensively evaluated by flow cytometry. Furthermore, associations between changes in immune cell frequencies and prognosis were determined.ResultsATI prolonged survival to 18.7 months compared with previous estimates of 6.2–11.1 months for patients treated with chemotherapy alone. ATI decreased CD3+CD4+CD8? T cell frequency in peripheral blood and increased CD3+CD4?CD8+ T cell frequency. An increase in CD3+ T cells and CD3+TCRγδ? T cells in peripheral blood after treatment was associated with a good prognosis.ConclusionsATI altered the immune profile in peripheral blood, including CD3+CD4?CD8+ T cells, and improved prognosis in pancreatic cancer. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
